Close Menu

CareDx

The company uses next-generation sequencing data to track the health of transplanted organs and stem cells over time.

The company is also continuing to expand its digital technology offering to help clinicians track their patients' health more easily.

The company reported $58.6 million in total revenues for the quarter and said testing services revenues rose 73 percent year over year.

News items for the in vitro diagnostics industry for the week of Feb. 8, 2021.

News items for the in vitro diagnostics industry for the week of Jan. 25, 2021.

The researchers hope that donor-derived cell-free DNA testing to monitor rejection can help relieve racial disparities in heart transplant outcomes.

The company said it will use the net proceeds from the offering for working capital and general corporate purposes.

CareDx expects fourth quarter revenues of $58.4 million to $58.6 million, an increase of approximately 63 percent compared to $35.8 million in Q4 2019.

News items for the in vitro diagnostics industry for the week of Jan. 4, 2021.

The test will identify more than 100 pathogens, as well as drug resistance in viruses and bacteria.

Pages